Divis Laboratories Ltd.
| BSE: 532488 | Sector: Health care |
| NSE: DIVISLAB | ISIN Code: INE361B01024 |
| BSE 00:00 | 04 Jan | 4621.65 |
-31.90 (-0.69%) |
OPEN
4672.85 |
HIGH
4678.70 |
LOW
4608.00 |
| NSE 00:00 | 04 Jan | 4621.70 |
-29.55 (-0.64%) |
OPEN
4652.10 |
HIGH
4679.95 |
LOW
4609.00 |
| OPEN | 4672.85 |
| PREVIOUS CLOSE | 4653.55 |
| VOLUME | 14096 |
| 52-Week high | 5425.00 |
| 52-Week low | 3154.50 |
| P/E | 58.21 |
| Mkt Cap.(Rs cr) | 122,682 |
| Buy Price | 0.00 |
| Buy Qty | 0.00 |
| Sell Price | 0.00 |
| Sell Qty | 0.00 |
About Divis Laboratories Ltd.
Divi's Laboratories Ltd is an India based manufacturer of Active Pharmaceutical Ingredients (APIs) and Intermediates. The company is engaged in manufacture of leading generic compounds Nutraceutical ingredients and custom synthesis of APIs and intermediates for global innovator companies. Divis is among the largest pharmaceutical companies in India with a portfolio of 120 products across diverse t...> More
Divis Laboratories Ltd - Key Fundamentals
| Parameter | Values | ||
| Market Cap | ( |
122,682 | |
| EPS - TTM | ( |
[*S] | 79.39 |
| P/E Ratio | (X) | [*S] | 58.21 |
| Face Value | ( |
2 | |
| Latest Dividend | (%) | 1000.00 | |
| Latest Dividend Date | 17 Aug 2021 | ||
| Dividend Yield | (%) | 0.43 | |
| Book Value / Share | ( |
[*S] | 372.89 |
| P/B Ratio | ( |
[*S] | 12.39 |
News
-
Multiple near-term concerns trigger Divi's Laboratories' headache
-
Pfizer's oral Covid-19 drug may hit revenues of Divi's Laboratories
-
Divis Labs falls 9% on weak operational performance in September quarter
-
Divis Labs surges 10%, hits record high in Monday's session; here's why
-
Lack of valuation comfort may limit gains in Divi's Laboratories stock
Announcement
-
Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results (Standalone And Con
-
Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended Septem
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Divi's Laboratories Limited - Analysts/Institutional Investor Meet/Con. Call Updates
Divis Laboratories Ltd - Financial Results
| Particulars ( |
Sep 2021 | Sep 2020 | % Chg |
| Net Sales | 1987.51 | 1749.3 | 13.62 |
| Other Income | 19.11 | 13.64 | 40.1 |
| Total Income | 2006.62 | 1762.94 | 13.82 |
| Total Expenses | 1169.44 | 1008.16 | 16 |
| Operating Profit | 837.18 | 754.78 | 10.92 |
| Net Profit | 606.46 | 519.59 | 16.72 |
| Equity Capital | 53.09 | 53.09 | - |
Divis Laboratories Ltd - Peer Group
| Company | Price( |
Chg (%) | Mkt Cap ( |
| Sun Pharma.Inds. | 837.95 | -1.21 | 201049.34 |
| Divi's Lab. | 4621.65 | -0.69 | 122681.70 |
| Dr Reddy's Labs | 4835.70 | -0.36 | 80475.72 |
| Cipla | 923.85 | -0.70 | 74536.22 |
| Piramal Enterp. | 2677.30 | -0.31 | 63893.76 |
Divis Laboratories Ltd - SHAREHOLDING PATTERN
|
|
|
Divis Laboratories Ltd - Research Reports
Divis Laboratories Ltd - RETURNS
| Period | BSE | NSE | Sensex | NIFTY |
| 1 Week | 2.14% | 2.13% | 3.38% | 3.32% |
| 1 Month | -2.85% | -2.85% | 3.74% | 3.54% |
| 3 Month | -11.48% | -11.47% | 0.94% | 0.64% |
| 6 Month | 2.22% | 2.26% | 14.04% | 13.25% |
| 1 Year | 19.65% | 19.66% | 24.24% | 25.98% |
| 3 Year | 216.83% | 216.45% | 67.69% | 65.98% |
Divis Laboratories Ltd - STOCK STRENGTH
| Today's Low/High | 4608.00 | 4678.70 | |
| Week Low/High | 4475.85 | 4708.00 | |
| Month Low/High | 4356.00 | 4800.00 | |
| YEAR Low/High | 3154.50 | 5425.00 | |
| All TIME Low/High | 7.70 | 5425.00 |
Quick Links for Divis Laboratories:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices


